Island Pharmaceuticals says new data leads to ISLA-101 Phase 2 study changes

June 3, 2024 Australian Biotech

This is a preview of subscriber content

Subscribe now to continue reading.

Australian antiviral drug development company Island Pharmaceuticals (ASX:ILA) has announced new data that are expected to introduce significant, quantifiable time and cost savings into its clinical program for dengue fever. …

Subscribe now to continue reading.

Latest Video

Historical change on pharmacy prescribing could be a sign of more to come
February 10, 2025 - Latest News
Victorian official appointed to HTA Review implementation advisory group
February 10, 2025 - Latest News
'Unfortunately, there remain significant gaps in knowledge among healthcare professionals when it comes to menopause'
February 10, 2025 - Latest News
Proponents of meaningful reform might consider pharmacy prescribing as a case study
February 11, 2025 - Latest News
Sandoz summit promotes reform to boost the use of biosimilars
February 11, 2025 - Latest News

Island Pharmaceuticals says new data leads to ISLA-101 Phase 2 study changes

This is a preview of subscriber content

Latest Video

Most Read

Historical change on pharmacy prescribing could be a sign of more to come

Victorian official appointed to HTA Review implementation advisory group

'Unfortunately, there remain significant gaps in knowledge among healthcare professionals when it comes to menopause'

Proponents of meaningful reform might consider pharmacy prescribing as a case study

Sandoz summit promotes reform to boost the use of biosimilars

New Stories

Immunoglobulin sales drives a strong first half for CSL but lower immunisation rates hit Seqirus

Rare Cancers Australia says election is the chance to end the ‘cancer lottery’

Specialised Therapeutics announces Thai approval of breast cancer therapy

Merck adds experienced industry executive to leadership team

Sandoz summit promotes reform to boost the use of biosimilars

AdvanCell extends collaboration with Lilly to advance novel targeted alpha therapies

Immunoglobulin sales drives a strong first half for CSL but lower immunisation rates hit Seqirus

Sign In

Island Pharmaceuticals says new data leads to ISLA-101 Phase 2 study changes

This is a preview of subscriber content

Latest Video

Most Read

Historical change on pharmacy prescribing could be a sign of more to come

Victorian official appointed to HTA Review implementation advisory group

'Unfortunately, there remain significant gaps in knowledge among healthcare professionals when it comes to menopause'

Proponents of meaningful reform might consider pharmacy prescribing as a case study

Sandoz summit promotes reform to boost the use of biosimilars

Follow Us

New Stories

Immunoglobulin sales drives a strong first half for CSL but lower immunisation rates hit Seqirus

Rare Cancers Australia says election is the chance to end the ‘cancer lottery’

Specialised Therapeutics announces Thai approval of breast cancer therapy

Merck adds experienced industry executive to leadership team

Sandoz summit promotes reform to boost the use of biosimilars

AdvanCell extends collaboration with Lilly to advance novel targeted alpha therapies

Immunoglobulin sales drives a strong first half for CSL but lower immunisation rates hit Seqirus